NASDAQ$OSUR

OraSure Technologies Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported Q1 2024 revenue of $54.1 million and GAAP EPS of $(0.05).

OraSure Technologies reported Q1 2024 revenue of $54.1 million. The company is undergoing restructuring initiatives expected to result in $15 million of annualized expense reductions and aims to achieve cash flow breakeven for its core business by the end of 2024. They also delivered initial orders for Syphilis Health Check™ as part of their distribution agreement with Diagnostics Direct.

  • Total net revenues for Q1 2024 decreased by 65% to $54.1 million compared to $155.0 million in Q1 2023.
  • Core revenue (excluding COVID-19 revenue) was $31.0 million, a 15% decrease year-over-year.
  • COVID-19 revenue decreased by 80% year-over-year to $23.1 million.
  • GAAP gross margin percentage was 44.5% compared to 42.5% in the same period last year.

Headline financials

Total Revenue

$54.1M

Previous: $155M-65.1%
EPS

-$0.05

Previous: $0.47-110.6%
Gross Margin

44.5%

No prior period
Non-GAAP Gross Margin

45.2%

No prior period
Operating Margin

-13.1%

No prior period
Non-GAAP Operating Margin

-0.6%

No prior period
Capital Expenditures

-$1.58M

Previous: -$1.19M-32.6%
Free Cash Flow

-$5.16M

Previous: $26M-119.8%
Net Income

-$3.58M

Previous: $27.2M-113.2%
Operating Income

-$7.09M

Previous: $24.3M-129.2%
Gross Profit

$24.1M

Previous: $65.8M-63.4%
Cash & Equivalents

$247M

Previous: $90.2M+174.0%
Total Assets

$468M

Previous: $459M+1.8%
R&D Expense

$7.74M

No prior period
Stock-Based Comp

$2.97M

Previous: $2.66M+11.8%

Revenue & EPS history

OraSure · Revenue · Quarterly

$54.1M

Q1 2024-65.1%vs Q1 2023
Beat estimate in 13 of 14 quarters(93%)
ActualEstimate

Forward guidance

The Company is guiding to Q2 2024 revenue of $50 to $55 million, which includes core revenue of $33 to $36 million and InteliSwab® revenue of $17 to $19 million. Our Q2 2024 guidance includes approximately $650 thousand of revenue from the Diversigen business that we plan to exit.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-2.1%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-2.4%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+31.7%

Q2 2023

Best reaction

-32.1%

Q2 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.2%-2.9%
Q4 2025+10.0%+6.4%+7.1%
Q3 2025-6.6%-4.3%-3.1%
Q1 2025-6.8%-5.0%+3.6%
Q4 2024-23.5%-10.8%-14.2%
Q3 2024-1.2%-1.2%-8.9%
Q2 2024+2.6%-0.2%+5.7%
Q1 2024-8.8%-6.9%-15.3%
Q4 2023+10.3%+3.7%-12.3%
Q3 2023+4.9%+14.5%+22.2%
Q2 2023+31.7%+43.9%+42.8%
Q1 2023+9.2%-20.8%-22.3%
Q4 2022+10.4%+18.8%+30.1%
Q3 2022+0.7%+20.8%+18.5%
Q2 2022+28.3%+38.6%+18.8%
Q1 2022-8.9%-3.9%-48.8%
Q4 2021-1.3%-0.8%-13.0%
Q3 2021-4.9%-7.7%-19.8%
Q2 2021+1.2%-0.7%-4.1%
Q1 2021+5.0%+5.1%+0.2%
Q4 2020-2.3%+2.1%+1.5%
Q3 2020-15.6%-15.4%-20.6%
Q2 2020-32.1%-24.6%-46.9%
Q1 2020+6.1%+15.6%-33.1%
Q4 2019-6.7%-6.1%+8.5%
Q3 2019-3.1%-6.9%-10.3%
Q2 2019-3.3%-5.2%-14.4%
Q1 2019-8.0%-12.6%-12.7%
Q4 2018-25.5%-18.3%-14.8%
Q3 2018-8.7%-6.6%-15.0%
Q2 2018-0.6%-1.0%-5.8%
Q1 2018-15.4%-11.0%-2.4%
Q4 2017-12.8%-13.4%-9.5%
Q3 2017-30.3%-26.6%-13.8%
Q2 2017+13.5%+19.4%+17.4%
Q1 2017+16.9%+10.9%+17.6%
Q4 2016+18.9%+18.9%+29.9%
Q3 2016-0.1%+1.4%+14.3%
Q2 2016+4.6%+8.5%+30.7%
Q1 2016-6.6%
Q4 2015+14.7%
Q3 2015+0.4%
Q2 2015+7.0%
Q1 2015-12.3%
Q4 2014-11.9%
Q3 2014+2.9%
Q2 2014-7.7%
Q1 2014-9.2%
Q4 2013+9.5%
Q3 2013-0.3%
Q2 2013+10.2%
Q1 2013-0.4%
Q4 2012-12.4%
Q3 2012-16.4%
Q2 2012-7.1%
Q1 2011+5.0%
Q1 2012-5.9%
Q4 2011+4.6%
Q3 2011-5.6%
Q4 2010-12.5%
Q2 2011-12.5%
Q3 2010+6.6%
Q2 2010-7.0%
Q1 2010-15.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro